Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| TCRX | 8-K | bearish | 7/10 | TScan Therapeutics disclosed that Amgen terminated their Research Collaboration and License Agreement for Crohn's diseas | Aug 18, 2026 |
| SAFX | 8-K | bearish | 7/10 | XCF Global entered into a $500,000 senior secured bridge loan with a $666,666 face value (25% OID) from Abri Capital Lim | Aug 18, 2026 |
| ABCL | CLUSTER | bullish | 5/10 | Three AbCellera insiders, including the CFO and two directors, purchased a total of ~$975K in open-market shares over a | Aug 18, 2026 |
| HELP | 6-K | neutral | 3/10 | Helus Pharma (CYBIN Inc.) announced the appointment of Regina Donohue as Chief People Officer and Dr. Suresh Durgam to i | Aug 18, 2026 |
| GSK | 6-K | neutral | 1/10 | GSK filed a Form 6-K disclosing routine dividend reinvestment transactions by three PDMRs (Dr. Hal Barron, James Ford, a | Aug 18, 2026 |
| OGN | INST-CLUSTER | bearish | 6/10 | A bearish institutional cluster emerged in Organon & Co. (OGN) during 2026-Q2, with 19 funds reducing positions (includi | Aug 18, 2026 |
| RFL | INST-CLUSTER | bullish | 6/10 | Five institutional investors significantly increased positions in Rafael Holdings in Q2 2026, led by Citadel (+364%), Ka | Aug 18, 2026 |
| BMRN | 8-K | bullish | 7/10 | BioMarin (BMRN) entered into a definitive Share Purchase Agreement to acquire Alesta Therapeutics for $275 million upfro | Aug 18, 2026 |
| BIAF | 8-K | neutral | 3/10 | bioAffinity Technologies announced a nationwide federal healthcare distribution agreement for its CyPath Lung diagnostic | Aug 18, 2026 |
| TTRX | 8-K | neutral | 4/10 | Turn Therapeutics disclosed that GEM Yield Bahamas Limited exercised a warrant to purchase 1,192,207 shares on a cashles | Aug 18, 2026 |
| PLRX | PRESS-RELEASE | bullish | 4/10 | Pliant Therapeutics announced FDA Fast Track designation for PLN-101095, an oral dual integrin inhibitor for ICI-refract | Aug 18, 2026 |
| PPCB | PRESS-RELEASE | neutral | 4/10 | Propanc Biopharma announced it is finalizing a clinical trial protocol and conducting a feasibility assessment for a Fir | Aug 18, 2026 |
| BAK | 6-K | mixed | 6/10 | Braskem's subsidiary Braskem Idesa has filed for Chapter 11 prepackaged restructuring in the U.S., with a consensual agr | Aug 18, 2026 |
| IMTX | 6-K | neutral | 6/10 | Immatics reported Q2 2026 financial results showing a net loss of €62.5M ($71.2M) on collaboration revenue of €9.1M ($10 | Aug 18, 2026 |
| AMLX | 8-K | bullish | 7/10 | Amylyx announced highly positive topline results from the Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglyc | Aug 18, 2026 |
| SPRC | PRESS-RELEASE | neutral | 4/10 | SciSparc invested C$2.7 million in its majority-owned subsidiary NeuroThera's non-brokered private placement, which rais | Aug 18, 2026 |
| ENTX | 8-K | neutral | 3/10 | Entera Bio appointed Dr. Riccardo Paolo Camisasca as Chief Medical Officer, effective immediately, to lead late-stage cl | Aug 18, 2026 |
| VRAX | 6-K | neutral | 3/10 | Virax Biolabs published an updated Q3 2026 investor presentation on its IR website, which is filed via Form 6-K. The fil | Aug 18, 2026 |
| GNPX | 8-K | neutral | 4/10 | Genprex announced a development and manufacturing agreement with a U.S.-based CDMO to scale up production of its diabete | Aug 18, 2026 |
| NVO | 6-K | neutral | 2/10 | Novo Nordisk filed a routine 6-K disclosing weekly share repurchase transactions under its existing DKK 15 billion buyba | Aug 18, 2026 |
| HCM | 6-K | neutral | 2/10 | HUTCHMED filed a routine 6-K disclosing that its Chairman, Dr. Dan Eldar, was formerly a director of S.D. Sight Diagnost | Aug 18, 2026 |
| CYPH | 8-K | neutral | 3/10 | Analysis based on filing metadata only, document content was unavailable. CYPHERPUNK TECHNOLOGIES INC. (CYPH) filed an 8 | Aug 18, 2026 |
| IMTX | PRESS-RELEASE | mixed | 6/10 | Immatics reported Q2 2026 earnings with a narrower-than-expected net loss per share of -$0.46 (€-0.46), beating consensu | Aug 18, 2026 |
| BAK | 6-K | bearish | 8/10 | Braskem disclosed that Fitch Ratings downgraded its global corporate credit rating to 'RD' (Restricted Default) followin | Aug 18, 2026 |
| APLM | CLUSTER | bullish | 8/10 | Three top executives at Apollomics (CEO, CFO, COO) collectively purchased $2.25M of APLM stock in open-market transactio | Aug 18, 2026 |
| DYN | CLUSTER | bearish | 6/10 | Director Jason P. Rhodes sold ~$65.2M worth of DYN shares (1.4% of market cap) in a cluster over two days, while CEO Joh | Aug 18, 2026 |
| ZVRA | CLUSTER | neutral | 3/10 | Two ZVRA insiders, the Chief Legal & Compliance Officer and a Director, sold a combined $613K in open-market transaction | Aug 18, 2026 |
| TNYA | 144 | bearish | 4/10 | Ali Faraz, an officer and director of Tenaya Therapeutics, filed a Form 144 notice of intent to sell 22,232 shares of co | Aug 17, 2026 |
| APLM | CLUSTER | bullish | 6/10 | Apollomics CFO and COO made open-market purchases totaling $700K at $15/share, representing ~1% of the $68M market cap. | Aug 17, 2026 |
| EWTX | CLUSTER | neutral | 4/10 | Five C-suite insiders at Edgewise Therapeutics sold a total of ~$401K in open-market shares on August 12, 2026, followin | Aug 17, 2026 |